Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Lord Lebedev, and are more likely to reflect personal policy preferences.
Lord Lebedev has not introduced any legislation before Parliament
Lord Lebedev has not co-sponsored any Bills in the current parliamentary sitting
In 2018, the United Kingdom’s Chief Medical Officer commissioned independent researchers at University College London to map published research on screen time, social media, and children and young people’s mental health. Their findings were published by the National Institute for Health Research.
On 7 February 2019, the Chief Medical Officer published a commentary on this research, alongside their advice for parents and carers, and their recommendations for other stakeholders. They determined that the evidence was insufficiently conclusive to support the Chief Medical Officer’s evidence-based guidelines on optimal amounts of screen use or online activities, such as social media use.
Ketamine does not have a marketing authorisation in the United Kingdom for use in the treatment of any mental health conditions. Esketamine nasal spray, an isomer of ketamine, is licensed for treatment-resistant depression that has not responded to at least two different antidepressants in the current moderate to severe depressive episode in adults, and for the treatment of adults with a moderate to severe episode of major depressive disorder, as acute short-term treatment for the rapid reduction of depressive symptoms, which, according to clinical judgement, constitutes a psychiatric emergency.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new, licenced medicines represent a clinically and cost-effective use of resources.
The NICE has been unable to recommend esketamine for treatment-resistant depression due to uncertainties in its clinical and cost-effectiveness. It is not therefore routinely funded by the NHS in England for any indication.
The NICE was unable to make recommendations on the use of esketamine nasal spray for the treatment of major depressive disorder because the marketing authorisation holder did not provide an evidence submission.